NAD+ precursor trial raises blood levels but misses functional endpoints
Taking an NAD+ supplement did raise the amount of the molecule in people's blood — that part works. But it did not make participants meaningfully stronger or faster over three months. A biomarker moving is not the same as a person getting healthier.
What happened
204 adults aged 60-80 received nicotinamide riboside or placebo for 12 weeks.
Blood NAD+ roughly doubled in the treated group, confirming the compound is absorbed and used.
Primary endpoints of grip strength and six-minute walk distance showed no significant difference; two inflammatory markers improved modestly.
Why it matters
This is the clearest recent example of the gap between biomarker change and functional benefit, which is the defining credibility problem in consumer longevity.
Twelve weeks may be too short to detect functional change in this population — a null result is not proof of no effect.
It reinforces the distinction between clinical NAD+ programmes held to trial standards and supplements sold on mechanism alone.
Evidence check
Optional scientific context: how much weight this finding can carry.
- 12 weeks is likely too short for functional endpoints in older adults.
- Participants were relatively healthy, limiting room for improvement.
- Secondary marker improvements were not corrected for multiple comparisons.
- Dose was at the lower end of the studied range.
LONGEFI Signal
LONGEFI's deterministic scientific synthesis — not a market view.
How strong the underlying evidence is.
How new or meaningfully different the finding is.
How close the evidence is to meaningful human application.
How likely this is to matter commercially or strategically.
LONGEFI Signal is a 0–100 comparison score across scientific evidence, novelty, human relevance and market relevance. It is not an investment rating and not a prediction of investment performance.LONGEFI Signal is a 0–100 comparison score built from four analytical dimensions — scientific evidence, novelty, human relevance and market relevance — so developments can be ranked against each other. NOT AN INVESTMENT RATING: it is not a prediction of investment performance and not a view on any security.
Science explained
The terminology, in plain language.
- NAD+
- A molecule every cell uses to produce energy and run repair processes. Levels fall with age.
- Precursor
- A raw ingredient the body converts into the molecule it actually needs.
- Primary endpoint
- The single result a trial is designed to prove. Missing it means the trial failed, whatever else improved.
- Secondary marker
- An additional measurement. Improvements here are suggestive, not conclusive.
What would change our view?
The findings that would raise or lower this Signal.
Longer trial
A 12-month design testing whether functional change simply needs more time.
Deficient population
Benefit shown in people with measurably depleted baseline NAD+.
Repeat nulls
Further trials reproducing the biomarker-to-benefit gap.
Dosing critique
Evidence the tested dose was too low to be informative.
Sources & traceability
Supporting documents, underlying datasets and independent sources are not the same thing.
- Trial publication
Cell Metabolism
Everything below is commercial interpretation. It does not form part of the LONGEFI Scientific Signal.
Companies & assets
Exposure to the technology discussed, not an investment view.
ChromaDex
CDXCThis development may be relevant to this company’s longevity programs.
Nicotinamide riboside (consumer NAD+)
Consumer revenue funds evidence generation, but the two must be judged separately.
Metro International Biotech
PrivateThis development may be relevant to this company’s longevity programs.
NAD+ precursors
NAD+ biology only becomes investable when it is held to a clinical evidence standard.
Market implications
Which parts of the field this touches, and over what horizon.
ChromaDex
Potentially challengedCommercialises NAD+ precursor supplements.
A null functional endpoint increases scrutiny of marketing claims built on blood-level changes.
Metro International Biotech
Long-term relevanceClinical-stage NAD+ modulators in defined indications.
Supports the argument that NAD+ needs disease-specific endpoints rather than general wellness claims.
- NAD+ precursors
- Inflammaging biomarkers
- Consumer supplements
- Nutraceuticals
- Clinical-stage metabolic therapeutics
Immediate relevance to consumer NAD+ marketing claims, which increasingly face regulatory scrutiny. Pharmaceutical NAD+ programmes are affected less, since they are powered for different endpoints.
LONGEFI does not issue buy, sell or hold recommendations, and nothing here is personalized financial advice.
Trend connections
How this connects to themes LONGEFI tracks over time.